Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine re­view

A bi­par­ti­san group of 34 at­tor­neys gen­er­al have asked the fed­er­al gov­ern­ment to by­pass Gilead’s patent rights on remde­sivir and be­gin scal­ing and dis­trib­ut­ing the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER